BMS Acquires Karuna in $14 Billion Deal
- Posted by ISPE Boston
- On January 4, 2024
Bristol Myers Squibb has agreed to acquire Boston-based biopharma Karuna Therapeutics for $330 per share in a transaction valued at $14 billion. Karuna is focused on therapies for psychiatric and neurological conditions with a lead asset called KarXT, an antipsychotic with a novel mechanism of action and differentiated efficacy and safety. Karuna’s NDA for KarXT […]
Read More